Tue, September 20, 2011
Mon, September 19, 2011
Sun, September 18, 2011
Sat, September 17, 2011
Fri, September 16, 2011
Thu, September 15, 2011
Wed, September 14, 2011
Tue, September 13, 2011
Mon, September 12, 2011
Sun, September 11, 2011
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011
Tue, September 6, 2011
Mon, September 5, 2011
Sun, September 4, 2011
Sat, September 3, 2011
Fri, September 2, 2011
Thu, September 1, 2011
Wed, August 31, 2011
Tue, August 30, 2011
[ Tue, Aug 30th 2011 ] - Market Wire
00 a.m. ET
Mon, August 29, 2011
Fri, August 26, 2011
Thu, August 25, 2011
Wed, August 24, 2011
Tue, August 23, 2011
Mon, August 22, 2011
Sat, August 20, 2011
Fri, August 19, 2011

BioCryst to Present at Three Upcoming Investor Conferences


//health-fitness.news-articles.net/content/2011/ .. sent-at-three-upcoming-investor-conferences.html
Published in Health and Fitness on Wednesday, September 7th 2011 at 2:21 GMT by Market Wire   Print publication without navigation


RESEARCH TRIANGLE PARK, N.C.--([ BUSINESS WIRE ])--[ BioCryst Pharmaceuticals, Inc. ] (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present a corporate summary and an update regarding the Companya™s [ clinical programs ] at the following investor conferences in New York:

  • Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011 at 2:00 p.m. Eastern time
  • Morgan Stanley Global Healthcare Conference on Tuesday, September 13, 2011 at 2:10 p.m. Eastern Time
  • JMP Securities Healthcare Conference on Tuesday, September 27, 2011 8:30 a.m. Eastern Time

Links to live audio webcasts and replays of both presentations may be accessed on the BioCryst website at [ www.BioCryst.com ].

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in infectious diseases, inflammatory diseases and cancer. BioCryst currently has three novel late-stage compounds: [ peramivir ], a neuraminidase inhibitor for the treatment of influenza, [ BCX4208 ], a purine nucleoside phosphorylase (PNP) inhibitor for the treatment of gout, and forodesine, an orally-available PNP inhibitor for hematological malignancies. Utilizing crystallography and [ structure-based drug design ], BioCryst continues to discover additional compounds and to progress others through pre-clinical and early development to address the unmet medical needs of patients and physicians. For more information, please visit the Company's website at [ www.biocryst.com ].

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at [ http://investor.shareholder.com/biocryst/sec.cfm ].

BCRXW


Publication Contributing Sources